Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2014. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility (PDMRs) related to the company's 401K plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory notification regarding internal plan transactions and does not contain financial performance data.
Material Changes
No material changes to the company's financial position or operations are reported. The filing details a revaluation of the cash element of the notional investment held within the GSK 401K plan, resulting in an increase in the notional allocation of American Depositary Shares (ADSs) for specific individuals on February 20, 2014, at a price of $56.22 per ADS.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is a compliance filing under Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).
Key Facts for Investor Verification
- The filing reports a notional increase in ADS allocations for Dr. M M Slaoui (15 ADSs), Dr. K Slaoui (13 ADSs), Mr. W C Louv (20 ADSs), and Mrs. D P Connelly (1 ADS).
- The transaction price for the notional allocation was $56.22 per ADS.
- The event was triggered by a revaluation of the cash element within the GSK 401K plan.
- No financial results or strategic updates are included in this specific report.